These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 18676614)
1. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Brines M; Patel NS; Villa P; Brines C; Mennini T; De Paola M; Erbayraktar Z; Erbayraktar S; Sepodes B; Thiemermann C; Ghezzi P; Yamin M; Hand CC; Xie QW; Coleman T; Cerami A Proc Natl Acad Sci U S A; 2008 Aug; 105(31):10925-30. PubMed ID: 18676614 [TBL] [Abstract][Full Text] [Related]
2. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Brines M; Cerami A Kidney Int; 2006 Jul; 70(2):246-50. PubMed ID: 16738535 [TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors. Brines M Blood Purif; 2010; 29(2):86-92. PubMed ID: 20093809 [TBL] [Abstract][Full Text] [Related]
4. Erythropoietin and its derivatives: from tissue protection to immune regulation. Peng B; Kong G; Yang C; Ming Y Cell Death Dis; 2020 Feb; 11(2):79. PubMed ID: 32015330 [TBL] [Abstract][Full Text] [Related]
5. Helix B surface peptide administered after insult of ischemia reperfusion improved renal function, structure and apoptosis through beta common receptor/erythropoietin receptor and PI3K/Akt pathway in a murine model. Yang C; Zhao T; Lin M; Zhao Z; Hu L; Jia Y; Xue Y; Xu M; Tang Q; Yang B; Rong R; Zhu T Exp Biol Med (Maywood); 2013 Jan; 238(1):111-9. PubMed ID: 23479770 [TBL] [Abstract][Full Text] [Related]
6. From Erythropoietin to Its Peptide Derivatives: Smaller but Stronger. Zhang C; Yang C; Zhu T Curr Protein Pept Sci; 2017; 18(12):1191-1194. PubMed ID: 27634443 [TBL] [Abstract][Full Text] [Related]
7. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Fiordaliso F; Chimenti S; Staszewsky L; Bai A; Carlo E; Cuccovillo I; Doni M; Mengozzi M; Tonelli R; Ghezzi P; Coleman T; Brines M; Cerami A; Latini R Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2046-51. PubMed ID: 15671158 [TBL] [Abstract][Full Text] [Related]
8. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. Brines M; Cerami A J Intern Med; 2008 Nov; 264(5):405-32. PubMed ID: 19017170 [TBL] [Abstract][Full Text] [Related]
9. Erythropoietin-mediated protection in kidney transplantation: nonerythropoietic EPO derivatives improve function without increasing risk of cardiovascular events. van Rijt WG; van Goor H; Ploeg RJ; Leuvenink HG Transpl Int; 2014 Mar; 27(3):241-8. PubMed ID: 23964738 [TBL] [Abstract][Full Text] [Related]
10. Renoprotection and Mechanisms of Erythropoietin and Its Derivatives Helix B Surface Peptide in Kidney Injuries. Zhang Y; Chen W; Wu Y; Yang B Curr Protein Pept Sci; 2017; 18(12):1183-1190. PubMed ID: 27634442 [TBL] [Abstract][Full Text] [Related]
11. Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin. Ueba H; Brines M; Yamin M; Umemoto T; Ako J; Momomura S; Cerami A; Kawakami M Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14357-62. PubMed ID: 20660739 [TBL] [Abstract][Full Text] [Related]
12. Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells. Bohr S; Patel SJ; Vasko R; Shen K; Iracheta-Vellve A; Lee J; Bale SS; Chakraborty N; Brines M; Cerami A; Berthiaume F; Yarmush ML J Mol Med (Berl); 2015 Feb; 93(2):199-210. PubMed ID: 25373867 [TBL] [Abstract][Full Text] [Related]
14. Discovery and Characterization of Nonpeptidyl Agonists of the Tissue-Protective Erythropoietin Receptor. Miller JL; Church TJ; Leonoudakis D; Lariosa-Willingham K; Frigon NL; Tettenborn CS; Spencer JR; Punnonen J Mol Pharmacol; 2015 Aug; 88(2):357-67. PubMed ID: 26018904 [TBL] [Abstract][Full Text] [Related]
15. The erythropoietin-derived peptide MK-X and erythropoietin have neuroprotective effects against ischemic brain damage. Yoo SJ; Cho B; Lee D; Son G; Lee YB; Soo Han H; Kim E; Moon C; Moon C Cell Death Dis; 2017 Aug; 8(8):e3003. PubMed ID: 28817120 [TBL] [Abstract][Full Text] [Related]
16. Mutant erythropoietin without erythropoietic activity is neuroprotective against ischemic brain injury. Gan Y; Xing J; Jing Z; Stetler RA; Zhang F; Luo Y; Ji X; Gao Y; Cao G Stroke; 2012 Nov; 43(11):3071-7. PubMed ID: 22984011 [TBL] [Abstract][Full Text] [Related]
17. Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Collino M; Thiemermann C; Cerami A; Brines M Pharmacol Ther; 2015 Jul; 151():32-40. PubMed ID: 25728128 [TBL] [Abstract][Full Text] [Related]
18. Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury. Patel NS; Kerr-Peterson HL; Brines M; Collino M; Rogazzo M; Fantozzi R; Wood EG; Johnson FL; Yaqoob MM; Cerami A; Thiemermann C Mol Med; 2012 May; 18(1):719-27. PubMed ID: 22415011 [TBL] [Abstract][Full Text] [Related]
19. Potential role of erythropoietin receptors and ligands in attenuating apoptosis and inflammation in critical limb ischemia. Joshi D; Abraham D; Shiwen X; Baker D; Tsui J J Vasc Surg; 2014 Jul; 60(1):191-201, 201.e1-2. PubMed ID: 24055514 [TBL] [Abstract][Full Text] [Related]
20. Erythropoietin pretreatment exerts anti-inflammatory effects in hepatic ischemia/reperfusion-injured rats via suppression of the TLR2/NF-κB pathway. Liu QS; Cheng ZW; Xiong JG; Cheng S; He XF; Li XC Transplant Proc; 2015 Mar; 47(2):283-9. PubMed ID: 25769561 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]